The pharmaceutical Merck agreed to allow other drug manufacturers around the world to produce its anti-drug pill COVID-19 with the intention of helping millions of people in the poorest countries, reported yesterday a public health organization backed by the UN.
The Medicines Patent Pool agency said in a statement that it signed a voluntary license agreement with Merck and his partner Ridgeback Biotherapeutics to produce molnupiravir.
The agreement would allow the Medicines Patent Pool to grant future licenses to companies authorized to produce the drug. Under the contract, no pharmaceutical company would receive royalties as long as the World Health Organization considers that the COVID-19 is a global emergency. Molnupiravir is the first pill that has been shown to be effective against this condition.
Charles Gore, executive director of the Medicines Patent Pool, said the first results for molnupiravir were “compelling” and that he hoped that the first voluntary license agreement for one treatment for COVID-19 would make way for others.